Skip to main content
HR 6383 116th Congress House

Uterine Fibroid Research and Education Act of 2020

Official title: To provide for research and education with respect to uterine fibroids, and for other purposes.

Introduced: March 24, 2020 Introduced by: Clarke, Yvette D. Democratic · New York See on congress.gov
Health Congressional oversightHealth care coverage and accessHealth personnelHealth promotion and preventive care
More subjectsShow fewer subjects
Health technology, devices, suppliesMedicaidMedical researchMinority healthPrescription drugsResearch administration and fundingSex and reproductive healthWomen's health
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 24, 2020
Referred to the House Committee on Energy and Commerce.
Mar 24, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action March 24, 2020

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Uterine Fibroid Research and Education Act of 2020

This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues).

Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies.

In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services.

Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6383: Uterine Fibroid Research and Education Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-HR-6383/
MLA
"H.R. 6383: Uterine Fibroid Research and Education Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-6383/.
Bluebook (legal)
H.R. 6383, 116th Cong. (2026), https://openamerica.io/bill/116-HR-6383/.
Markdown link
[H.R. 6383: Uterine Fibroid Research and Education Act of 2020](https://openamerica.io/bill/116-HR-6383/)
Report a problem